- Home
- YI vs VTGN Comparison
YI vs VTGN Comparison
Compare YI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- VTGN
- Stock Information
- Founded
- YI 2010
- VTGN 1998
- Country
- YI China
- VTGN United States
- Employees
- YI N/A
- VTGN N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- VTGN Health Care
- Exchange
- YI Nasdaq
- VTGN Nasdaq
- Market Cap
- YI 70.0M
- VTGN 59.8M
- IPO Year
- YI N/A
- VTGN N/A
- Fundamental
- Price
- YI $7.32
- VTGN $3.08
- Analyst Decision
- YI
- VTGN
- Analyst Count
- YI 0
- VTGN 0
- Target Price
- YI N/A
- VTGN N/A
- AVG Volume (30 Days)
- YI 10.6K
- VTGN 374.7K
- Earning Date
- YI 08-28-2025
- VTGN 08-12-2025
- Dividend Yield
- YI N/A
- VTGN N/A
- EPS Growth
- YI N/A
- VTGN N/A
- EPS
- YI N/A
- VTGN N/A
- Revenue
- YI $1,984,717,013.00
- VTGN $486,000.00
- Revenue This Year
- YI N/A
- VTGN $23.83
- Revenue Next Year
- YI N/A
- VTGN $660.39
- P/E Ratio
- YI N/A
- VTGN N/A
- Revenue Growth
- YI N/A
- VTGN N/A
- 52 Week Low
- YI $4.15
- VTGN $1.90
- 52 Week High
- YI $12.60
- VTGN $3.79
- Technical
- Relative Strength Index (RSI)
- YI 42.76
- VTGN 75.81
- Support Level
- YI $7.10
- VTGN $2.25
- Resistance Level
- YI $7.65
- VTGN $2.83
- Average True Range (ATR)
- YI 0.18
- VTGN 0.21
- MACD
- YI 0.01
- VTGN 0.07
- Stochastic Oscillator
- YI 28.27
- VTGN 84.16
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.